The Quiet Consolidation Happening in Your Dermatologist’s Office
Walk into a dermatology office in a mid-size American city today and the waiting room might look the same as it did five years ago – same recessed lighting, same skin care product displays, same front desk staff. But the ownership structure behind that practice has very likely changed. Private equity firms have been moving through regional dermatology markets with speed and discipline, acquiring independent practices one by one, folding them into larger platform companies, and preparing those platforms for eventual resale at multiples that would have seemed absurd to any solo dermatologist who built their practice from scratch in the 1990s.
This is not a fringe financial trend. The dermatology sector has become one of the most actively targeted specialties in physician practice management deals, alongside ophthalmology and gastroenterology. The economics make sense for investors: dermatology is largely cash-pay or well-reimbursed, demand is reliably growing, and most regional practices are run by physicians who want to retire without the complexity of a traditional succession plan. PE firms show up at exactly the right moment – with capital, operational infrastructure, and an offer that removes administrative headaches in exchange for a controlling stake.
Why Dermatology Became a Target
The specialty has a profile that private equity firms actively seek. Procedures are high-margin, the payer mix leans favorable – often blending medical dermatology visits with cosmetic services that are paid entirely out of pocket – and patients return regularly. A single dermatologist running a moderately busy practice can generate strong annual revenue, and when several practices are grouped together under shared back-office infrastructure, the combined margin improves substantially. Billing, credentialing, HR, compliance – all of those costs get spread across a larger base, and the savings flow directly to the platform’s valuation.
There’s also the supply problem. Dermatology has one of the longest wait times for new patient appointments of any specialty, and there are no signs that residency slots will expand fast enough to change that. PE-backed platforms can hire nurse practitioners and physician assistants to fill schedule gaps, which increases visit volume without proportionally increasing physician cost. That model only works at scale, which is precisely the point of rolling up regional practices into a single managed entity.
Independent dermatologists also face real operational pressure that has nothing to do with patient care. Insurance negotiations, electronic health record costs, malpractice insurance, and the administrative burden of running a small business have all intensified over the past decade. Selling to a PE-backed group can feel less like cashing out and more like a relief valve. The physician often stays on as an employee, keeps their patient relationships, and hands the business problems to someone else – at least initially.
How the Deals Actually Work
Most regional dermatology acquisitions follow a similar structure. A PE firm acquires a large anchor practice – often a group with multiple locations and established revenue – and uses it as the platform. Smaller surrounding practices are then added as add-ons, typically at lower purchase price multiples than the anchor received. Physicians in those smaller practices usually receive a combination of upfront cash and an equity stake in the platform, with the expectation that the platform will eventually sell to a larger buyer, a hospital system, or a strategic acquirer, at which point the equity gets monetized. The whole cycle can run anywhere from three to seven years.
This pattern is not unique to dermatology. Regional eye care practices have followed nearly identical consolidation paths, with ophthalmology groups absorbed into PE-backed vision platforms that compete on scale rather than independent identity. The mechanics copy across specialties with minor variation.
What Changes After the Sale
The early months after an acquisition are often smooth. The PE firm has every incentive to keep physicians happy during the integration period – departures before the platform stabilizes damage valuations. Staff stays, schedules remain largely intact, and the acquiring group signals continuity. The friction tends to arrive later, when operational mandates designed to improve margin start colliding with clinical workflow preferences that physicians didn’t think to negotiate before signing.
Productivity targets are the most common point of tension. PE-backed dermatology platforms frequently implement metrics around patients seen per hour, which can work fine for experienced dermatologists with efficient workflows but can push newer or slower-paced physicians toward a volume-first model that wasn’t part of their original practice culture. Cosmetic service quotas or soft targets can also create awkward dynamics in practices that were previously focused on medical dermatology, where the clinical and aesthetic arms of the business had clearer separation.
Patient experience changes tend to be more subtle. Brand names shift as the local practice gets folded into the platform’s identity. Appointment availability may actually improve initially, as the platform’s investment in support staff helps clear backlogs. But the physician continuity that many dermatology patients depend on – particularly patients managing chronic conditions like psoriasis or eczema who have built relationships with a specific doctor over years – can erode if physician turnover increases under the new operating model.
There is also a pricing dimension that rarely gets discussed openly. PE-backed platforms negotiate aggressively with insurers once they reach scale, sometimes successfully, sometimes not – and in markets where negotiations break down, the platform may quietly drop certain insurance plans or shift volume toward cash-pay and cosmetic services, which carry better margins but are less accessible to lower-income patients. This has drawn regulatory attention in some states, though enforcement has been sporadic and largely reactive.
What remains genuinely unresolved is where the consolidation ceiling sits. Dermatology has a finite number of independent practices available for acquisition in any given region, and the most attractive markets – suburban metros with strong demographics and high cosmetic spend – are already being contested by multiple competing platforms. The deals that were straightforward three years ago are getting more complicated as sellers have wised up to the valuation game and are arriving at negotiations with their own advisors, their own comparable transaction data, and a much clearer understanding of what their equity rollover is actually worth. Whether the second wave of buyers – the strategic acquirers who will eventually absorb these platforms – will pay the multiples that make the entire structure profitable for early investors is the question that no one inside these deals is answering out loud.
